DS
CLRB icon

DRW Securities’s Cellectar Biosciences CLRB Stock Holding History

DRW Securities’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-45,190
Closed -$133K – 1355
2025
Q4 		$133K Buy
45,190
+24,089
+114% +$88.9K ﹤0.01% 1027
2025
Q3 		$118K Buy
+21,101
New +$105K ﹤0.01% 1168

Other funds holding CLRB

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $300M AUM 10.98% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

DRW Securities's CLRB Position: Q1 2026 in Review

DRW Securities sold out of Cellectar Biosciences (CLRB) in Q1 2026, closing a stake of 45,190 shares — an estimated $133K sold.

DRW Securities first reported a position in CLRB in Q3 2025 and held it in 2 quarters. The position peaked at $133K in Q4 2025. 19 funds tracked by Wall St. Rank hold CLRB as of Q1 2026.

  • DRW Securities reported no remaining Cellectar Biosciences position as of Q1 2026 after selling out during the quarter.
  • DRW Securities sold 45,190 Cellectar Biosciences shares in Q1 2026, an estimated $133K.
  • DRW Securities first reported a position in Cellectar Biosciences in Q3 2025 and held it in 2 quarters.
  • DRW Securities's Cellectar Biosciences position peaked at $133K in Q4 2025.
  • 19 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.